Effect of Continuous Positive Airway Pressure Treatment on Inflammation in Patients With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effects of CPAP treatment on airway and systemic inflammation in obstructive sleep apnea.
Obstructive Sleep Apnea
Continuous Positive Airway Pressure
Device: CPAP treatment
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Longitudinal Study of Short-Term Effects of CPAP Treatment on Airway and Systemic Inflammation in Patients With Obstructive Sleep Apnea|
- Inflammatory biomarkers in induced sputum and blood. Cell counts in induced sputum. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- NO in exhaled breath [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Airway resistance [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- PSG measurement(AHI,etc.) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Quality of Life [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Psychological status [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Sleep quality [ Time Frame: 3 months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2009|
|Study Completion Date:||March 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Device: CPAP treatment
maintains upper airway patency and minimizes the obstructive events
Other Name: REMstar(Respironics), SleepMate(ResMed)
Obstructive sleep apnea (OSA) is characterised by repetitive episodes of upper airway obstruction during sleep. Systemic and airway inflammation has been recently shown to be associated with OSA and is hypothesized to contribute to the clinical manifestation and the complications of OSA patients.
Continuous positive airway pressure (CPAP) is a first-line treatment for OSA and improves diurnal and nocturnal symptoms. However, the effectiveness of CPAP in reversing airway inflammation is less compelling in comparison to systemic inflammation.
This study will assess NO in exhaled breath, inflammatory biomarkers in induced sputum and blood of OSA patients and other clinical measurements before and after 3 months of CPAP treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00780923
|Kyoto University Graduate School of Medicine|
|Kyoto, Japan, 6068507|
|Principal Investigator:||Kazuo Chin, MD,PhD||Kyoto University, Graduate School of Medicine|
|Principal Investigator:||Toru Oga, MD,PhD||Kyoto University, Graduate School of Medicine|